Paclitaxel
别名: NSC 125973,PTX
中文名称:紫杉醇
目录号:S1150 Purity: 99.99%
Paclitaxel是一种microtubule聚合物稳定剂,在人内皮细胞中IC50为0.1 pM。Paclitaxel可引起有丝分裂停滞和细胞凋亡。 Paclitaxel还会诱导自噬。
CAS: 33069-62-4
客户使用Selleck的Paclitaxel发表文献482篇
- Nat Cancer, 2023 4(9):1362-1381
- Nat Cell Biol, 2023 25(2):309-322
- Science, 2022 375(6586):1254-1261
- Cancer Cell, 2022 40(10):1207-1222.e10
- Cell Res, 2022 10.1038/s41422-022-00651-9
- Cell, 2021 184(25):6119-6137.e26
- Cancer Cell, 2021 S1535-6108(21)00659-0
- Cancer Cell, 2021 S1535-6108(20)30658-9
- Nat Immunol, 2021 22(4):485-496
- Cancer Discov, 2021 11(2):362-383
- Cell Stem Cell, 2021 S1934-5909(21)00385-4
- Cancer Cell, 2020 38(5):672-684.e6
- Cell Discov, 2020 28;6:26
- Nat Cancer, 2020 1(2):235-248
- Nat Med, 2019 25(5):838-849
- Cell, 2019 36(2):179-193
- Cancer Cell, 2019 36(2):179-193
- Mol Cancer, 2019
- Cancer Discov, 2019 9(2):230-247
- Nat Cell Biol, 2019 21(2):238-250
- Nat Med, 2018 24(7):954-960
- Adv Mater, 2018 30(43):e1801621
- Nature, 2017 551(7679):247-250
- Science, 2017 eaal3755
- Cell Stem Cell, 2017 21(5):650-664
- Bioact Mater, 2025 43:67-81
- Nat Commun, 2024 15(1):2503
- Nat Commun, 2024 15(1):2089
- Adv Sci (Weinh), 2024 11(5):e2305035
- Cell Rep Med, 2024 5(7):101627
- Cell Rep Med, 2024 5(5):101519
- Cell Death Differ, 2024 10.1038/s41418-024-01267-9
- Cell Death Differ, 2024 10.1038/s41418-024-01277-7
- Theranostics, 2024 14(6):2442-2463
- Clin Cancer Res, 2024 30(16):3481-3498
- J Exp Clin Cancer Res, 2024 43(1):127
- Cancer Res, 2024
- EMBO Mol Med, 2024
- J Adv Res, 2024 S2090-1232(24)00413-2
- Clin Transl Med, 2024 14(2):e1567
- Sci Data, 2024 11(1):1024
- Cancer Lett, 2024 586:216695
- Int J Biol Sci, 2024 20(7):2403-2421
- Cell Death Dis, 2024 15(8):603
- Cell Death Dis, 2024 15(7):480
- Cell Rep, 2024 43(10):114784
- Cell Prolif, 2024 e13728.
- Cell Commun Signal, 2024 22(1):375
- Acta Pharmacol Sin, 2024 10.1038/s41401-023-01219-y
- Oncogene, 2024 10.1038/s41388-024-03231-w
- Int J Nanomedicine, 2024 19:3847-3859
- NPJ Precis Oncol, 2024 8(1):53
- J Cell Biol, 2024 223(8)e202206046
- Cell Oncol (Dordr), 2024 10.1007/s13402-024-00939-5
- iScience, 2024 27(3):109052
- iScience, 2024 27(6):110027
- iScience, 2024 27(4):109580
- Cancer Cell Int, 2024 24(1):249
- Int J Mol Sci, 2024 25(19)10863
- Front Pharmacol, 2024 15:1257941
- Int J Mol Sci, 2024 25(4)2167
- Int J Mol Sci, 2024 25(3)1769
- Biomolecules, 2024 14(7)741
- J Cell Mol Med, 2024 28(7):e18198
- Int J Oncol, 2024 64(4)34
- Transl Oncol, 2024 43:101857
- Polymers (Basel), 2024 16(21)3087
- Eur J Pharm Biopharm, 2024 S0939-6411(24)00126-7
- Ther Adv Med Oncol, 2024 16:17588359241303302
- J Biol Chem, 2024 300(6):107375
- Front Oncol, 2024 14:1389472
- Sci Rep, 2024 14(1):10075
- BMC Cancer, 2024 24(1):55
- J Mater Sci-Mater M, 2024 35(1):32
- PLoS One, 2024 19(11):e0307153
- Invest New Drugs, 2024 42(4):471-477.
- Mol Biol Cell, 2024 35(12):ar151
- Photochem Photobiol, 2024 10.1111/php.13957
- Anticancer Res, 2024 44(12):5271-5282
- Sci Adv, 2024 10(11):eadk0785
- World J Oncol, 2024 15(3):492-505
- World J Oncol, 2024 15(2):192-208
- Nat Commun, 2023 14(1):556
- Nat Commun, 2023 14(1):7576
- Nat Commun, 2023 14(1):3366
- Nat Commun, 2023 14(1):3450
- Nat Commun, 2023 14(1):6505
- Adv Sci (Weinh), 2023 10(17):e2207257
- Cell Rep Med, 2023 10.1016/j.xcrm.2023.101277
- Cell Rep Med, 2023 S2666-3791(23)00315-4
- Proc Natl Acad Sci U S A, 2023 120(7):e2215308120
- J Control Release, 2023 363:235-252
- Cell Death Dis, 2023 14(1):64
- Cell Rep, 2023 42(10):113176
- Cell Rep, 2023 10.1016/j.celrep.2023.113347
- Oncogene, 2023 42(14):1117-1131
- JCI Insight, 2023 8(12)e161675
- Microsyst Nanoeng, 2023 10.1038/s41378-023-00607-y
- Biomed Pharmacother, 2023 160:114350
- Cells, 2023 12(16)2052
- iScience, 2023 26(1):105723
- Int J Mol Sci, 2023 24(9)7751
- Int J Mol Sci, 2023 24(6)5993
- Cancer Cell Int, 2023 23(1):204
- Cancers (Basel), 2023 16(1)107
- Cancers (Basel), 2023 15(23)5576
- Transl Oncol, 2023 32:101656
- Neoplasia, 2023 10.1016/j.neo.2023.100949
- Front Oncol, 2023 13:1104594
- Front Oncol, 2023 13:1190988
- Front Oncol, 2023 13:1178021
- Biomedicines, 2023 11(5)1270
- Molecules, 2023 28(4)1948
- Sci Rep, 2023 13(1):16271
- Cell Physiol Biochem, 2023 57(4):212-225
- J Cancer, 2023 14(6):1011-1023
- Cytokine, 2023 10.1016/j.cyto.2023.156370
- Int J Med Sci, 2023 20(9):1220-1234
- Neoplasma, 2023 10.4149/neo_2023_230404N185
- Hum Exp Toxicol, 2023 42:9603271231158047
- Technol Cancer Res Treat, 2023 22:15330338231202307
- Breast Cancer (Dove Med Press), 2023 10.2147/BCTT.S430513
- bioRxiv, 2023 2023.05.02.539080
- HOKKAIDO UNIVERSITY, 2023 10.14943/doctoral.k15648
- Mol Cell, 2022 82(1):75-89.e9
- J Clin Invest, 2022 132(24)e151604
- Adv Sci (Weinh), 2022 9(28):e2201889
- Nat Chem Biol, 2022 10.1038/s41589-022-00996-7
- Acta Pharm Sin B, 2022 12(12):4407-4423
- J Exp Clin Cancer Res, 2022 41(1):312
- J Exp Clin Cancer Res, 2022 41(1):58
- EMBO Mol Med, 2022 14(2):e14903
- J Immunother Cancer, 2022 10-9e005199
- Clin Transl Med, 2022 12(2):e747
- Cancer Immunol Res, 2022 10(7):829-843
- Cell Death Dis, 2022 13(5):500
- Cell Chem Biol, 2022 29(10):1517-1531.e7
- Cell Prolif, 2022 e13322
- Acta Pharmacol Sin, 2022 10.1038/s41401-021-00847-6
- JCI Insight, 2022 7(22e158060)
- Oncogene, 2022 41(31):3859-3875
- Oncogene, 2022 41(13):1974-1985
- NPJ Precis Oncol, 2022 6(1:81)
- Elife, 2022 11e75231
- Biomed Pharmacother, 2022 153:113528
- Biomed Pharmacother, 2022 152:113230
- J Transl Med, 2022 20(1):290
- Cell Death Discov, 2022 8(1):296
- Cell Death Discov, 2022 8(1):235
- NPJ Breast Cancer, 2022 8(1):44
- iScience, 2022 25(10):105182
- Clin Epigenetics, 2022 14(1):147
- Front Bioeng Biotechnol, 2022 10:855755
- Int J Mol Sci, 2022 23(9)5070
- Front Pharmacol, 2022 13:951831
- Front Pharmacol, 2022 13:924523
- Front Pharmacol, 2022 13:895744
- Front Pharmacol, 2022 13:1032975
- Front Pharmacol, 2022 13:795613
- Int J Mol Sci, 2022 23(10)5532
- Biomolecules, 2022 12-81155
- Pharmaceutics, 2022 14(7)1450
- Pharmaceutics, 2022 14(4)837
- Cancers (Basel, 2022 14(184532)
- Cancers (Basel), 2022 14(18)4357
- Cancers (Basel), 2022 14(3)779
- Eur J Pharmacol, 2022 919:174802
- Eur J Pharmacol, 2022 922:174875
- J Pers Med, 2022 12(2)258
- Bioengineered, 2022 13(2):2076-2086
- Front Oncol, 2022 12:1068443
- Front Oncol, 2022 12:821391
- Sci Rep, 2022 12(1):6345
- Sci Rep, 2022 12(1):1049
- Traffic, 2022 23(5):270-286
- Hum Cell, 2022 10.1007/s13577-022-00671-y
- Mol Cell Biochem, 2022 10.1007/s11010-022-04470-9
- Future Med Chem, 2022 14(7):479-500
- J Cancer, 2022 13(15):3660-3673
- Breast Cancer Res Treat, 2022 192(1):75-87
- Cancer Biol Ther, 2022 23(1):65-75
- Biochem Biophys Res Commun, 2022 610:1-7
- Asian J Androl, 2022 24(6):643-652
- Fundam Clin Pharmacol, 2022 10.1111/fcp.12759
- Pharmacol Res Perspect, 2022 10(5):e01016
- Cancer Genomics Proteomics, 2022 19(3):328-338
- J Breast Cancer, 2022 25(6):500-512
- Sci Adv, 2022 8(44):eabq5914
- Cancer Diagn Progn, 2022 2(5):533-541
- Nat Commun, 2021 12(1):5404
- Nat Commun, 2021 12(1):1213
- J Clin Invest, 2021 131(1)136779
- Acta Pharm Sin B, 2021 11(12):3935-3949
- Biomaterials, 2021 272:120770
- Cell Death Differ, 2021 10.1038/s41418-021-00827-7
- J Exp Clin Cancer Res, 2021 40(1):276
- J Exp Clin Cancer Res, 2021 40(1):302
- Cancer Res, 2021 canres.2276.2020
- Cancer Res, 2021 canres.2125.2020
- Clin Transl Med, 2021 11(11):e578
- Adv Healthc Mater, 2021 e2001896
- Cancer Lett, 2021 S0304-3835(21)00436-5
- Cancer Lett, 2021 526:53-65
- Pharmacol Res, 2021 174:105927
- Pharmacol Res, 2021 S1043-6618(21)00453-9
- Int J Biol Sci, 2021 17(12):3224-3238
- Cell Death Dis, 2021 12(12):1135
- Br J Cancer, 2021 10.1038/s41416-021-01639-9
- Cell Rep, 2021 34(10):108814
- Cell Rep, 2021 35(13):109291
- Br J Cancer, 2021 10.1038/s41416-021-01658-6
- Acta Pharmacol Sin, 2021 10.1038/s41401-021-00691-8
- Oncogene, 2021 10.1038/s41388-021-02097-6
- Int J Nanomedicine, 2021 16:2173-2186
- Elife, 2021 10e68714
- Cell Biosci, 2021 11(1):124
- Biomacromolecules, 2021 10.1021/acs.biomac.1c01295
- Commun Biol, 2021 4(1):358
- Commun Biol, 2021 4(1):178
- NPJ Breast Cancer, 2021 7(1):111
- NPJ Breast Cancer, 2021 7(1):154
- NPJ Breast Cancer, 2021 7(1):79
- Cancer Cell Int, 2021 21(1):42
- Cancer Sci, 2021 112(10):4166-4175
- Int J Mol Sci, 2021 22(15)8083
- Front Pharmacol, 2021 12:714566
- Int J Mol Sci, 2021 22(3)1223
- Int J Mol Sci, 2021 22(10)5384
- Front Pharmacol, 2021 12:781282
- Am J Physiol Cell Physiol, 2021 10.1152/ajpcell.00116.2021
- Nanomedicine (Lond), 2021 16(12):997-1015
- Front Cell Dev Biol, 2021 9:687522
- Mol Cancer Res, 2021 molcanres.0342.2021
- Cancers (Basel), 2021 13(2)E361
- Cancers (Basel), 2021 13(11)2539
- Cancers (Basel), 2021 13(4)653
- Cancers (Basel), 2021 13(7)1739
- Biochim Biophys Acta Mol Cell Res, 2021 1869(2):119174
- Chem Biol Interact, 2021 340:109448
- J Nat Prod, 2021 84(2):298-309
- Transl Oncol, 2021 14(10):101181
- Eur J Pharmacol, 2021 907:174222
- Front Oncol, 2021 11:738534
- Front Oncol, 2021 11:667689
- Front Oncol, 2021 11:618540
- Front Oncol, 2021 11:752127
- Sci Rep, 2021 11(1):21304
- Sci Rep, 2021 11(1):14253
- Sci Rep, 2021 11(1):20812
- Pharmaceuticals (Basel), 2021 14(7)682
- J Inflamm Res, 2021 14:4901-4913
- Hum Cell, 2021 10.1007/s13577-021-00639-4
- Hum Cell, 2021 10.1007/s13577-021-00579-z
- Hum Cell, 2021 34(6):1911-1918
- J Cancer, 2021 12(14):4277-4287
- J Cancer, 2021 12(1):65-75
- J Cancer, 2021 12(6):1634-1643
- BMC Cancer, 2021 21(1):65
- PLoS One, 2021 16(2):e0236074
- Invest New Drugs, 2021 10.1007/s10637-020-01003-3
- Biochem Biophys Res Commun, 2021 589:85-91
- Cancer Chemother Pharmacol, 2021 10.1007/s00280-021-04322-1
- Chem Biol Drug Des, 2021 10.1111/cbdd.13977
- Oncol Lett, 2021 21(2):82
- Pathol Res Pract, 2021 224:153535
- Pathol Oncol Res, 2021 27:1609976
- Clin Res Hepatol Gastroenterol, 2021 S2210-7401(21)00158-3
- Exp Ther Med, 2021 22(3):935
- Int J Radiat Biol, 2021 1-16
- J Pharmacokinet Pharmacodyn, 2021 10.1007/s10928-021-09795-4
- Rapid Commun Mass Spectrom, 2021 e9195
- Sci Adv, 2021 7(6)eabc8346
- J Int Med Res, 2021 49(10):3000605211044368
- Theranostics, 2020 10(6):2727-2743
- Clin Cancer Res, 2020 27 pii: clincanres
- Cancer Res, 2020 10.1158/0008-5472.CAN-19-3466
- J Immunother Cancer, 2020 8(1)
- J Immunother Cancer, 2020 8(2)e000807
- Cancer Lett, 2020 472:59-69
- Cell Death Dis, 2020 13;11(5):362
- Cell Death Dis, 2020 11(11):976
- Cell Death Dis, 2020 11(10):822
- Cell Death Dis, 2020 11(9):790
- Cell Rep, 2020 32(10):108102
- Cell Rep, 2020 31(13):107840
- Cell Rep, 2020 33(11):108493
- Oncogene, 2020 39(2):454-468
- J Cell Biol, 2020 4;219(5):e201909094
- Biomed Pharmacother, 2020 16;127:110225
- Biomed Pharmacother, 2020 129:110441
- Life Sci, 2020 246:117428
- Stem Cell Reports, 2020 8(6): 1617–1629
- Cancer Cell Int, 2020 19;20:58
- Mol Cancer Ther, 2020 molcanther.1160.2019
- Mol Cancer Ther, 2020 19(2):637-649
- Mol Ther Oncolytics, 2020 18:579-586
- Int J Mol Sci, 2020 30;21(3) pii: E903
- J Cell Physiol, 2020 10.1002/jcp.30110
- Int J Mol Sci, 2020 21(12):E4452
- Front Pharmacol, 2020 11:666
- Front Cell Dev Biol, 2020 8:601972
- Oncotarget, 2020 11(30):2873-2888
- Oncotarget, 2020 17;11(11):969-981
- Am J Cancer Res, 2020 10(8):2649-2676
- Am J Cancer Res, 2020 10(10):3302-3315
- Cancers (Basel), 2020 13;12(4) pii: E964
- Front Oncol, 2020 1.4125
- Front Oncol, 2020 10:1354
- Sci Rep, 2020 10(1):10805
- Sci Rep, 2020 15;10(1):337
- Sci Rep, 2020 10(1):12308
- Sci Rep, 2020 10(1):13124
- Sci Rep, 2020 10(1):20343
- Hum Cell, 2020 10.1007/s13577-020-00425-8
- Hum Cell, 2020 10.1007/s13577-020-00420-z
- J Cancer, 2020 26;11(12):3645-3654
- Cell Biol Int, 2020 10.1002/cbin.11481
- Cell Biol Int, 2020 44(2):610-620
- RSC Adv, 2020 10(71):43607-43618
- Acta Biochim Biophys Sin (Shanghai), 2020 gmaa072
- Front Genet, 2020 11:1000
- Cancer Biol Ther, 2020 21(5):452-462
- Clin Transl Oncol, 2020 10.1007/s12094-020-02484-7
- Cancer Manag Res, 2020 20;12:2641-2651
- Cancer Chemother Pharmacol, 2020 10.1007/s00280-020-04195-w
- Cancer Chemother Pharmacol, 2020 86(2):295-305
- Oncol Lett, 2020
- Fundam Clin Pharmacol, 2020 10.1111/fcp.12641
- Anticancer Res, 2020 40(7):3659-3667
- Mol Cell Oncol, 2020 7(6):1805094
- Nat Commun, 2019 10(1):5367
- Nat Commun, 2019 10(1):620
- Cell Death Differ, 2019 10.1038/s41418-019-0441-3
- Cell Death Differ, 2019 26(11):2300-2313
- Redox Biol, 2019 22:101131
- J Immunother Cancer, 2019 7(1):199
- J Control Release, 2019 294:165-175
- Cell Death Dis, 2019 10(9):660
- Cell Rep, 2019 27(11):3331-3344
- Oncogene, 2019 38(18):3371-3386
- Cell Biosci, 2019 9:20
- Breast Cancer Res, 2019 21(1):64
- Br J Pharmacol, 2019 176(12):2079-2094
- Life Sci, 2019 224:255-262
- Cells, 2019 8(7)
- Cells, 2019 8(6)
- Biochem Pharmacol, 2019 170:113642
- Colloids Surf B Biointerfaces, 2019 183:110396
- Mol Cancer Ther, 2019
- Int J Mol Med, 2019
- J Virol, 2019 93(4)
- Oncotarget, 2019 10(49):5011-5019
- Oncotarget, 2019 10(38):3667-3680
- Int J Oncol, 2019 55(4):938-948
- Mol Cancer Res, 2019 10.1158/1541-7786.MCR-18-0923
- Cancers (Basel), 2019 11(12)E1835
- Cancers (Basel), 2019 11(12)
- Chem Biol Interact, 2019 315:108886
- J Biol Chem, 2019 294(46):17471-17486
- J Biol Chem, 2019 294(20):8161-8170
- J Biol Chem, 2019 10.1074/jbc.RA119.010732
- Sci Rep, 2019 9(1):1897
- Sci Rep, 2019 9(1):19384
- Sci Rep, 2019 9(1):11153
- Mol Cell Endocrinol, 2019 498:110585
- Biosci Rep, 2019 39(8)
- Onco Targets Ther, 2019 12:9899-9913
- PLoS One, 2019 14(10):e0223555
- Mol Pharmacol, 2019 96(6):711-719
- J Pharmacol Exp Ther, 2019 369(3):531-545
- Hum Mol Genet, 2019 28(24):4043-4052
- AAPS PharmSciTech, 2019 20(5):198
- Cancer Biomark, 2019 10.3233/CBM-190460
- Biochem Biophys Res Commun, 2019 514(4):1154-1159
- Oncol Lett, 2019 17(1):990-998
- Pathol Res Pract, 2019 215(10):152606
- Orthop Surg, 2019 11(1):126-134
- Biomed Rep, 2019 10(4):218-224
- World J Clin Oncol, 2019 10(6):222-233
- Sci Transl Med, 2018 10(433)
- Nat Commun, 2018 9(1):4116
- Nat Commun, 2018 13;9(1):2720
- Clin Cancer Res, 2018 24(13):3197-3203
- J Control Release, 2018 283:223-234
- Mol Syst Biol, 2018 14(8):e8238
- Cancer Lett, 2018 420:60-71
- ACS Appl Mater Interfaces, 2018 10(26):21825-21835
- Cell Death Dis, 2018 9(2):42
- Cell Death Dis, 2018 9(5):559
- Cell Death Dis, 2018 9(11):1134
- Cell Death Dis, 2018 9(7):743
- Elife, 2018 7e32838
- Biochem Pharmacol, 2018 155:102-109
- Front Pharmacol, 2018 9:403
- Int J Mol Sci, 2018 19(10)
- Front Pharmacol, 2018 9:1116
- Oncotarget, 2018 9(44):27363-27379
- Transl Oncol, 2018 11(6):1406-1418
- Mol Pharm, 2018
- J Biol Chem, 2018 293(24):9461-9472
- Neoplasia, 2018 20(8):826-837
- Cell Physiol Biochem, 2018 47(2):489-504
- Cell Physiol Biochem, 2018 48(5):2046-2060
- Cell Cycle, 2018 17(21-22):2447-2459
- J Cell Sci, 2018 131(1)
- J Clin Med, 2018 7(12)
- DNA Repair (Amst), 2018 63:1-9
- BMC Cancer, 2018 18(1):1225
- Int J Med Sci, 2018 15(7):738-747
- Fitoterapia, 2018 125:174-183
- Cancer Manag Res, 2018 10:6695-6703
- Cancer Chemother Pharmacol, 2018 81(2):255-267
- Oncol Lett, 2018 15(5):6107-6114
- Methods Mol Biol, 2018 1686:201-213
- Mol Cell, 2017 68(1):210-223e6
- Mol Ther, 2017
- Clin Cancer Res., 2017 23(15):4364-4375
- Cancer Res, 2017 77(2):532-544
- Proc Natl Acad Sci U S A, 2017 114(18):E3729-E3738
- Clin Chem, 2017 63(10):1633-1641
- Oncogene, 2017 36(12):1707-1720
- Breast Cancer Res, 2017 19(1):93
- Stem Cell Reports, 2017 8(6):1617-1629
- Mol Cancer Ther, 2017 16(1):3-15
- Mol Cancer Ther, 2017 77(22):6282-6298
- Mol Cancer Ther, 2017 16(7):1377-1388
- Front Cell Infect Microbiol, 2017 7:146
- Mol Ther Oncolytics, 2017 5:75-86
- Respir Res, 2017 18(1):52
- Oncotarget, 2017 8(31):51733-51747
- Oncotarget, 2017 8(25):40654-40667
- Oncotarget, 2017
- Oncotarget, 2017
- Oncotarget, 2017 8(12):19738-19759
- Oncotarget, 2017 9(1):249-267
- Am J Cancer Res, 2017 7(4):903-912
- Int J Oncol, 2017 51(1):257-268
- Sci Rep, 2017 7(1):6600
- Oncol Rep, 2017 38(4):2205-2210
- ACS Omega, 2017
- J Cancer, 2017 8(9):1655-1664
- Biol Reprod, 2017 97(4):598-611
- J Pharmacol Exp Ther, 2017 363(1):20-34
- Exp Biol Med (Maywood), 2017 242(15):1490-1498
- SLAS Discov, 2017 22(5):507-515
- Exp Ther Med, 2017 14(5):4263-4271
- World J Clin Oncol, 2017 8(1):54-66
- Curr Protoc Chem Biol, 2017 9(2):55-74
- Nat Chem Biol, 2016 10.1038/nchembio.2082
- Proc Natl Acad Sci U S A, 2016 113(32):9015-20
- Chin Med J (Engl), 2016 129(20):2469-2475
- NPJ Breast Cancer, 2016 2:16033
- Colloids Surf B Biointerfaces, 2016 143:463-471
- Mol Cancer Ther, 2016 15(10):2302-2313
- Oncotarget, 2016 7(21):30977-89
- Oncotarget, 2016 7(27):41811-41824
- Mol Pharm, 2016 13(11):3724-3735
- Cell Cycle, 2016 15(19):2608-2618
- PLoS One, 2016 11(5):e0155052
- Cancer Biol Ther, 2016 17(12):1240-1252
- Cancer Res, 2015 75(2):446-55
- Environ Sci Technol, 2015 49(6):3575-83
- J Control Release, 2015 220(Pt B):727-37
- ACS Appl Mater Interfaces, 2015 10.1021/am5090226
- Apoptosis, 2015 20(10):1373-87
- Int J Radiat Oncol, 2015 91(4):807-16
- Biochem Pharmacol, 2015 96(3):168-78
- Oncotarget, 2015 6(27):23358-71
- Biotechnol Bioeng, 2015 112(8):1673-82
- Surgery, 2015 157(3):590-8
- PLoS One, 2015 10(4):e0123901
- PLoS One, 2015 10(7):e0134306
- Biomacromolecules, 2014 15(11):4187-94
- Mol Pharmacol, 2014 85(3):408-19
- Biochem Biophys Res Commun, 2014 453(3):392-7
- J Mater Chem B, 2013 1(42):5742-5750
- J Gen Virol, 2013 94(Pt 12):2750-8
- Am J Physiol Heart Circ Physiol, 2012 71(13):4707-19
- BMC Cancer, 2012 12:541
- Bioorg Med Chem, 2012 21(4):922-31
- RSC Adv, 2011 1:884-892
- Gynecol Oncol, 2003 90(3 Pt 2):S16-21
化学信息&溶解度
分子量 | 853.91 |
分子式 | C47H51NO14 |
CAS号 | 33069-62-4 |
Smiles | CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C |
储存条件(自收到货起) | |
建议分装储备液,避免反复冻融! |
|
体外溶解度 | 批次: |
DMSO : 100 mg/mL ( 117.1 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 23 mg/mL Water : Insoluble DMSO : 100 mg/mL ( 117.1 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 20 mg/mL Water : Insoluble DMSO : 100 mg/mL ( 117.1 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 90 mg/mL Water : Insoluble DMSO : 100 mg/mL ( 117.1 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 100 mg/mL Water : Insoluble DMSO : 100 mg/mL ( 117.1 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 25 mg/mL Water : Insoluble |
体内溶解度 | 批次: |
现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂 | |
5%DMSO
40%PEG300
5%Tween80
50%ddH2O
浓度:6mg/ml
(7.03mM)
操作示例:以 1 mL 工作液为例,取50μL120mg/ml的澄清DMSO储备液加到 400μL PEG300中,混合均匀使其澄清;向上述体系中加入50μLTween80,混合均匀使其澄清;然后继续加入500μL ddH2O定容至 1 mL。工作液请现配现用!
|
|
5%DMSO
5%Tween80
90%ddH2O
浓度:2mg/ml
(2.34mM)
操作示例:以 1 mL 工作液为例,取50 μL 40mg/ml的澄清DMSO储备液加入50 μL Tween80,混合均匀使其澄清;然后继续加入900 μL ddH2O定容至1mL。工作液请现配现用!
|
|
5%DMSO
40%PEG300
5%Tween80
50%ddH2O
浓度:5mg/ml
(5.86mM)
操作示例:以 1 mL 工作液为例,取50μL100mg/ml的澄清DMSO储备液加到400μLPEG300中,混合均匀使其澄清;向上述体系中加入50μLTween80,混合均匀使其澄清;然后继续加入500μLddH2O定容至1mL。工作液请现配现用!
|
摩尔浓度计算器
质量(g)= 浓度(mol/L)* 体积(L)* 分子量(g/mol)
动物体内配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,注:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入 μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
体内配方配制方法:取 μL DMSO母液,加入 μL Corn oil,混匀澄清。
注意:
1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。